Squarepoint’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-63,500
Closed -$427K 4737
2025
Q4
$427K Sell
63,500
-86,900
-58% -$655K ﹤0.01% 3337
2025
Q3
$1.3M Hold
150,400
﹤0.01% 2452
2025
Q2
$948K Sell
150,400
-700
-0.5% -$4.63K ﹤0.01% 2708
2025
Q1
$969K Sell
151,100
-174,900
-54% -$1.45M ﹤0.01% 2693
2024
Q4
$2.62M Buy
326,000
+299,800
+1,144% +$2.89M ﹤0.01% 2182
2024
Q3
$331K Buy
+26,200
New +$338K ﹤0.01% 3382
2022
Q1
Sell
-20,100
Closed -$2.88M 3312
2021
Q4
$2.88M Hold
20,100
0.01% 1054
2021
Q3
$4.17M Hold
20,100
0.01% 863
2021
Q2
$4.27M Buy
+20,100
New +$3.68M 0.02% 798

Other funds holding NVAX

Squarepoint's NVAX Position: Q2 2026 in Review

Squarepoint opened a new position in Novavax (NVAX) in Q2 2026: 133,562 shares worth $1.26M. The stake represents ﹤0.01% of the portfolio and ranks #2721 among its holdings. This is a return to the name: Squarepoint previously reported a position in NVAX as recently as Q2 2025.

Squarepoint first reported a position in NVAX in Q3 2015 and has held it in 27 quarters since. The position peaked at $11.6M in Q2 2022. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Squarepoint held 133,562 shares of Novavax worth $1.26M as of Q2 2026.
  • Novavax was a new Squarepoint position in Q2 2026.
  • Novavax made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2721 holding.
  • Squarepoint first reported a position in Novavax in Q3 2015 and has held it in 27 quarters since.
  • Squarepoint's Novavax position peaked at $11.6M in Q2 2022.
  • 268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.